Vivani Medical announced that it brought in $10 million in equity financing as it progresses its drug delivery technology.

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clini ...

Vivani Medical, Inc. ( ($VANI) ) has released its Q2 earnings. Here is a breakdown of the information Vivani Medical, Inc. presented to its ...

Vivani Medical ( ($VANI) ) has shared an update. On August 11, 2025, Vivani Medical entered into a Share Purchase Agreement to sell 7,936,507 ...

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing ...

Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clini ...

LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTMimplant technology, showed a positive safety and tolerability profile, along with encouraging performance data for NPM-115 that met t ...

Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss ...

How long should it take for Semaglutide to work? Semaglutide is the active ingredient in the weight loss medication Wegovy and the diabetes drugs Ozempic and Rybelsus, which are sometimes taken ...

Find the latest Vivani Medical, Inc. (VANI) stock quote, history, news and other vital information to help you with your stock trading and investing.

Oral semaglutide was associated with more pronounced cardiovascular benefits among patients with higher baseline HbA1c in type 2 diabetes.

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs.